In malignant melanoma, BRAF- and MEK inhibitor-tolerant cells exhibit multiple transcriptional states [181] and, over the last years, a number of acquired resistance mechanisms were discovered (reviewed in [12,13] and Figure 3). The gene discussed is BRAF; the disease is melanoma.